Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast

被引:130
作者
Solin, LJ
Fourquet, A
Vicini, FA
Taylor, M
Olivotto, IA
Haffty, B
Strom, EA
Pierce, LJ
Marks, LB
Bartelink, H
McNeese, MD
Jhingran, A
Wai, E
Bijker, N
Campana, F
Hwang, WT
机构
[1] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Inst Curie, Dept Radiat Oncol, Paris, France
[3] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI USA
[4] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, St Louis, MO USA
[5] British Columbia Canc Agcy, Radiat Therapy Program, Victoria, BC, Canada
[6] Yale Univ, Dept Radiat Oncol, New Haven, CT USA
[7] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[8] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[9] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC USA
[10] Netherlands Canc Inst, Dept Radiat Oncol, Amsterdam, Netherlands
[11] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
关键词
ductal carcinoma in situ; breast-conservation treatment; radiation therapy; local failure;
D O I
10.1002/cncr.20886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Ductal carcinoma in situ (DCIS) is detected most commonly on routine screening mammography in the asymptomatic patient, and has a long natural history. The objective of the current study was to determine the long-term outcome after breast-conservation surgery followed by definitive breast irradiation for women with mammographically detected DCIS of the breast. METHODS. In total, 1003 women with unilateral, mammographically detected DCIS of the breast underwent breast-conserving surgery followed by definitive breast irradiation. These women were treated in 10 institutions in North America and Europe. The median follow-up was 8.5 years (mean, 9.0 years; range, 0.2-24.6 years). RESULTS. The 15-year overall survival rate was 89%, and the 15-year cause-specific survival rate was 98%. The 15-year rate of freedom from distant metastases was 97%. In total, there were 100 local failures (10%) in the treated breast. The 15-year rate of an, local failure was 19%, and the 15-year rate of local only first failure was 16%. Patient age greater than or equal to 50 years at the time of treatment and negative final pathology margins from the primary tumor excision both were associated independently with a lower risk of local failure in univariate analysis (P = 0.00062 and P = 0.024, respectively) and in multivariate analysis (P = 0.00057 and P = 0.0026, respectively). For favorable subgroups of patients age greater than or equal to 50 years or with negative resection margins, the 10-year risk of local failure was less than or equal to 8%. CONCLUSIONS. The current results support the use of breast-conserving surgery followed by definitive breast irradiation for the treatment of patients with mammographically detected DCIS of the breast. Patient age greater than or equal to 50 years at the nine of treatment and negative resection margins both were associated independently with a decreased risk of local failure.
引用
收藏
页码:1137 / 1146
页数:10
相关论文
共 63 条
[1]  
Allred DC, 2002, BREAST CANCER RES TR, V76, pS36
[2]  
[Anonymous], 2002, AJCC cancer staging manual, P223, DOI [10.1007/978-1-4757-3656-4, DOI 10.1007/978-1-4757-3656-4]
[3]   RECURRENCE AFTER LUMPECTOMY FOR COMEDO-TYPE INTRADUCTAL CARCINOMA OF THE BREAST [J].
BAIRD, RM ;
WORTH, A ;
HISLOP, G .
AMERICAN JOURNAL OF SURGERY, 1990, 159 (05) :479-481
[4]   Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853 [J].
Bijker, N ;
Peterse, JL ;
Duchateau, L ;
Julien, JP ;
Fentiman, IS ;
Duval, C ;
Di Palma, S ;
Simony-Lafontaine, J ;
de Mascarel, I ;
van de Vijver, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2263-2271
[5]   Breast-conserving therapy for ductal carcinoma in situ of the breast:: The French Cancer Centers' experience [J].
Cutuli, B ;
Cohen-Solal-Le Nir, C ;
de Lafontan, B ;
Mignotte, H ;
Fichet, V ;
Fay, R ;
Servent, V ;
Giard, S ;
Charra-Brunaud, C ;
Lemanski, C ;
Auvray, H ;
Jacquot, S ;
Charpentier, JC .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (04) :868-879
[6]   Incidence of and treatment for ductal carcinoma in situ of the breast [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Grady, D ;
Henderson, IC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12) :913-918
[7]   RADIATION-THERAPY FOR TREATMENT OF INTRADUCTAL CARCINOMA OF THE BREAST [J].
FINDLAY, P ;
GOODMAN, R .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1983, 6 (03) :281-285
[8]   Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
Wickerham, DL ;
Fisher, ER ;
Mamounas, E ;
Smith, R ;
Begovic, M ;
Dimitrov, NV ;
Margolese, RG ;
Kardinal, CG ;
Kavanah, MT ;
Fehrenbacher, L ;
Oishi, RH .
LANCET, 1999, 353 (9169) :1993-2000
[9]   Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience [J].
Fisher, B ;
Land, S ;
Mamounas, E ;
Dignam, J ;
Fisher, ER ;
Wolmark, N .
SEMINARS IN ONCOLOGY, 2001, 28 (04) :400-418
[10]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685